Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Ebenezer A. Kio"'
Autor:
Thomas E. Witzig, Michael B. Tomblyn, Jamal G. Misleh, Ebenezer A. Kio, Robert M. Sharkey, William A. Wegener, David M. Goldenberg
Publikováno v:
Haematologica, Vol 99, Iss 11 (2014)
A lingering criticism of radioimmunotherapy in non-Hodgkin lymphoma is the use of cold anti-CD20 antibody along with the radiolabeled anti-CD20 antibody. We instead combined radioimmunotherapy with immunotherapy targeting different B-cell antigens. W
Externí odkaz:
https://doaj.org/article/78dc7ab480264fe09565bfce3e4eef85
Autor:
Christopher D. Fegan, Juliane M. Jürgensmeier, Pankaj Bhargava, Ziqian Zhou, Xi Huang, Rita Humeniuk, Ping Cheng Yi, Siddhartha S. Mitra, Martin J.S. Dyer, Lionel Karlin, Ebenezer A. Kio, Simon A. Rule, Peter Hillmen, Harriet S. Walter, Charles Herbaux, Alexey V. Danilov
Supplemental Figure 3. Mean (SD) TIRA plasma concentration. Cycle 1 Day 8 data are shown in patients receiving TIRA monotherapy with A) TIRA/IDELA, and B) TIRA/ENTO*
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11dcc13096ac288a3c0fe922698b5f6f
https://doi.org/10.1158/1078-0432.22476726.v1
https://doi.org/10.1158/1078-0432.22476726.v1
Autor:
David M. Goldenberg, Robert M. Sharkey, William A. Wegener, Boyd Mudenda, Pius P. Maliakal, Serengulam V. Govindan, Wells A. Messersmith, Ronald Scheff, Kevin Kalinsky, Leena Gandhi, Tirrell Johnson, Allyson Ocean, Bryan J. Schneider, Charles J. Schneider, Jamal Misleh, Michael J. Guarino, W. Thomas Purcell, Gregory A. Masters, Ebenezer A. Kio, D. Ross Camidge, Alexander N. Starodub, Rebecca S. Heist, Jhanelle E. Gray
Purpose: We evaluated a Trop-2–targeting antibody conjugated with SN-38 in metastatic small cell lung cancer (mSCLC) patients.Experimental Design: Sacituzumab govitecan was studied in patients with pretreated (median, 2; range, 1–7) mSCLC who rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85d3221b48c4ae9f44d5518d04b2e195
https://doi.org/10.1158/1078-0432.c.6526244.v1
https://doi.org/10.1158/1078-0432.c.6526244.v1
Autor:
Christopher D. Fegan, Juliane M. Jürgensmeier, Pankaj Bhargava, Ziqian Zhou, Xi Huang, Rita Humeniuk, Ping Cheng Yi, Siddhartha S. Mitra, Martin J.S. Dyer, Lionel Karlin, Ebenezer A. Kio, Simon A. Rule, Peter Hillmen, Harriet S. Walter, Charles Herbaux, Alexey V. Danilov
Supplemental Table 1 summarizes study inclusion and exclusion criteria. Supplemental Table 2 shows the doses and dose-escalation strategy used in this study. Supplemental Table 3 defines the dose-limiting toxicities that guided dose escalation. Suppl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2661752db628906be946811e30742a6f
https://doi.org/10.1158/1078-0432.22476717
https://doi.org/10.1158/1078-0432.22476717
Autor:
Christopher D. Fegan, Juliane M. Jürgensmeier, Pankaj Bhargava, Ziqian Zhou, Xi Huang, Rita Humeniuk, Ping Cheng Yi, Siddhartha S. Mitra, Martin J.S. Dyer, Lionel Karlin, Ebenezer A. Kio, Simon A. Rule, Peter Hillmen, Harriet S. Walter, Charles Herbaux, Alexey V. Danilov
Supplemental Figure 4. Free BTK levels at baseline and trough TIRA concentration for CLL patients treated with 80 mg TIRA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14a30975b8192d0017300139da2604cd
https://doi.org/10.1158/1078-0432.22476720.v1
https://doi.org/10.1158/1078-0432.22476720.v1
Autor:
David M. Goldenberg, Robert M. Sharkey, William A. Wegener, Boyd Mudenda, Pius P. Maliakal, Serengulam V. Govindan, Wells A. Messersmith, Ronald Scheff, Kevin Kalinsky, Leena Gandhi, Tirrell Johnson, Allyson Ocean, Bryan J. Schneider, Charles J. Schneider, Jamal Misleh, Michael J. Guarino, W. Thomas Purcell, Gregory A. Masters, Ebenezer A. Kio, D. Ross Camidge, Alexander N. Starodub, Rebecca S. Heist, Jhanelle E. Gray
Immunohistology expression of Trop-2 vs response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39c28d7d0d017206cdcb8eeb9b98c5f6
https://doi.org/10.1158/1078-0432.22466114
https://doi.org/10.1158/1078-0432.22466114
Autor:
Christopher D. Fegan, Juliane M. Jürgensmeier, Pankaj Bhargava, Ziqian Zhou, Xi Huang, Rita Humeniuk, Ping Cheng Yi, Siddhartha S. Mitra, Martin J.S. Dyer, Lionel Karlin, Ebenezer A. Kio, Simon A. Rule, Peter Hillmen, Harriet S. Walter, Charles Herbaux, Alexey V. Danilov
Supplemental Figure 2. Patient disposition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de2f892b658eb79b3f7169372bcb174e
https://doi.org/10.1158/1078-0432.22476729
https://doi.org/10.1158/1078-0432.22476729
Autor:
Christopher D. Fegan, Juliane M. Jürgensmeier, Pankaj Bhargava, Ziqian Zhou, Xi Huang, Rita Humeniuk, Ping Cheng Yi, Siddhartha S. Mitra, Martin J.S. Dyer, Lionel Karlin, Ebenezer A. Kio, Simon A. Rule, Peter Hillmen, Harriet S. Walter, Charles Herbaux, Alexey V. Danilov
Purpose:Bruton tyrosine kinase (BTK) inhibition alone leads to incomplete responses in chronic lymphocytic leukemia (CLL). Combination therapy may reduce activation of escape pathways and deepen responses. This open-label, phase Ib, sequential dose-e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf6dda7779f6dd51726c8df152e2017a
https://doi.org/10.1158/1078-0432.c.6529473
https://doi.org/10.1158/1078-0432.c.6529473
Autor:
David M. Goldenberg, Robert M. Sharkey, William A. Wegener, Boyd Mudenda, Pius P. Maliakal, Serengulam V. Govindan, Wells A. Messersmith, Ronald Scheff, Kevin Kalinsky, Leena Gandhi, Tirrell Johnson, Allyson Ocean, Bryan J. Schneider, Charles J. Schneider, Jamal Misleh, Michael J. Guarino, W. Thomas Purcell, Gregory A. Masters, Ebenezer A. Kio, D. Ross Camidge, Alexander N. Starodub, Rebecca S. Heist, Jhanelle E. Gray
Evaluation of IHC staining vs best overall response in SCLC treated with 8 or 10 mg/kg starting dose of sacituzumab govitecan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b47b04cd98cbbe62d66c192352ea6bce
https://doi.org/10.1158/1078-0432.22466111
https://doi.org/10.1158/1078-0432.22466111
Autor:
D. Ross Camidge, Martin Dunbar, Jyoti D. Patel, Jeffrey M. Clarke, Bruce A. Bach, Eddie Thara, Francisco Robert, Silpa Nuthalapati, Ebenezer A. Kio, Minh H. Dinh
Publikováno v:
Lung Cancer. 161:180-188
Objectives Both combinations of the PARP inhibitor veliparib plus platinum doublet chemotherapy (CT), and the programmed death receptor-1 (PD-1) inhibitor nivolumab plus CT have demonstrated encouraging efficacy for treatment of non-small cell lung c